The Role of the Gut Microbiome on Chronic Kidney Disease

Area of Science:

• Nephrology
• Microbiology
• Cardiology

Background:

• Chronic kidney disease (CKD) affects nearly 500 million people globally, with cardiovascular disease (CVD) being a primary cause of mortality.
• Traditional CVD risk interventions are often ineffective in CKD patients, highlighting the need for novel therapeutic targets.
• Gut dysbiosis, an imbalance in the gut microbiome, is increasingly recognized as a contributing factor in CKD pathogenesis and CVD risk.

Purpose of the Study:

• To review the current understanding of gut dysbiosis in CKD.
• To explore the role of gut dysbiosis in CKD pathophysiology and its association with cardiovascular risk.
• To discuss potential strategies for preventing and treating gut dysbiosis in CKD.

Main Methods:

• Review of current scientific literature on gut microbiome alterations in CKD.
• Analysis of the pathophysiological mechanisms linking gut dysbiosis to CKD and CVD.
• Discussion of emerging therapeutic and preventive strategies targeting gut dysbiosis.

Main Results:

• CKD is associated with specific gut microbiome changes, including reduced levels of beneficial bacteria (e.g., Bifidobacteriaceae, Lactobacillaceae) and increased levels of potentially harmful bacteria (e.g., Enterobacteriaceae).
• Gut dysbiosis is implicated as a non-traditional risk factor contributing to cardiovascular complications and disease progression in CKD patients.
• Current metagenomic techniques may lack the resolution to detect species-level alterations within bacterial genera, necessitating further research.

Conclusions:

• Gut dysbiosis is a critical factor in CKD progression and associated cardiovascular risks.
• Targeting gut dysbiosis presents a promising avenue for novel therapeutic interventions in CKD management.
• Further research is needed to fully elucidate the complex interplay between gut microbiota, CKD, and cardiovascular outcomes.